Long-lived self-renewing memory lymphocytes are a hallmark feature of the adaptive immune system in response to pathogens and tumors^[@R1]--[@R3]^. Analogous to organ systems in which non-replicating, terminally-differentiated cells are continually replenished by the progeny of less differentiated stem cells, it has been suggested that memory cells might contain stem cell-like cells^[@R4],[@R5]^. Indeed, several characteristics of stem cells can be found to certain degrees in memory B and T cells, including selective transcriptional profiles^[@R6]^, the capacity to self-renewal and the multipotency to differentiate into progeny with diverse fates^[@R4],[@R5]^.

The memory T-cell compartment is heterogeneous and has been conventionally divided into two subsets based on the expression of the lymph node homing molecules CD62L and CCR7^[@R7]^. Central memory T cells (T~CM~) express high levels of CD62L and CCR7 and were thought to be the stem cell-like memory subset, whereas CD62L^−^ CCR7^−^ effector memory T cells (T~EM~) are considered committed progenitor cells that undergo terminal differentiation after a limited number of divisions^[@R4],[@R5]^. The identification in mice of a novel population of memory T cells with enhanced stem cell-like qualities compared to conventional T~CM~ cells adds complexity to this dichotomous view^[@R8],[@R9]^. These memory T cells, which were designated memory stem cells (T~SCM~), exhibit a CD44^low^ CD62L~high~ phenotype like naïve T cells (T~N~), but co-express stem cell antigen--1 (Sca-1) and high levels of the antiapoptotic molecule B cell lymphoma 2 (Bcl-2), the β chain of the IL-2 and IL-15 receptor (IL2-Rβ), and the chemokine (C-X-C motif) receptor CXCR3^[@R8],[@R9]^. Whether a similar memory T-cell population exists in human is currently under intensive investigation^[@R10]^.

A human CD8^+^ memory T-cell population has been described that shares phenotypic and functional characteristics with hematopoietic stem cells including the expression of the stem cell marker C-KIT and the ability to efflux cellular toxins through the ATP-binding cassette (ABC)--superfamily multidrug efflux protein ABCB1^[@R11]^. However, recent data revealed that these cells are predominantly Vα7.2^+^ mucosal associated invariant T cells (MAIT)^[@R12]^. More recently, Schenkel *et al.*^[@R13]^ speculated that CD4^dim^CD8^bright^ T cells expressing high levels of β-catenin, a molecule associated with the generation of mouse T~SCM~^[@R9],[@R14]^, represent human T~SCM~, but the definitive identification of human T~SCM~ remains to be accomplished.

Identification of human T memory stem cells {#S1}
===========================================

We previously found that mouse T~SCM~ can be generated effectively in vitro by triggering Wnt signaling during T cell priming using Wnt3A or inhibitors of glycogen synthase kinase-3β (GSK-3β)^[@R9],[@R14],[@R15]^. We sought to employ the same strategy to generate candidate human T~SCM~ by activating CD45RO^−^CD62L^+^ naïve CD8^+^ T cells in the presence of the GSK-3β inhibitor TWS119 ([Fig. 1a](#F1){ref-type="fig"}). After two weeks, the majority of T cells cultured with TWS119 retained a CD45RO^−^CD62L^+^ naïve-like phenotype, whereas in the absence of GSK-3β inhibition, T cells uniformly upregulated the memory marker CD45RO ([Fig. 1a](#F1){ref-type="fig"}). To determine whether the CD45RO^−^CD62L^+^ T cells generated in the presence of TWS119 were truly naïve cells or had acquired memory traits, we performed an extensive phenotypic analysis using established markers of T-cell activation and differentiation ([Fig. 1b](#F1){ref-type="fig"})^[@R16]^. The vast majority of molecules (CD45RA, CCR7, CD27, IL-2Rα, IL-7Rα, CD69, 41BB, CCR5 and CD57) showed a similar expression pattern between T~N~ and TWS119-generated naïve-like T cells ([Fig. 1b](#F1){ref-type="fig"}). However, the naïve-like T cells expressed levels of CD95 and IL-2Rβ similar to conventional memory T cells ([Fig. 1b](#F1){ref-type="fig"}). Thus, we hypothesized that the expression of CD95 and IL-2Rβ on otherwise phenotypically naïve T cells could identify human T~SCM~ cells.

To determine if candidate T~SCM~ cells occur naturally we used polychromatic flow cytometry (PFC)^[@R17]^. Based on previous data^[@R17]^, we employed a highly stringent criterion of 7 markers to accurately define T~N~. Strikingly, a CD95^+^IL-2Rβ^+^ subset could be found in CD45RO^−^CCR7^+^CD45RA^+^CD62L^+^CD27^+^CD28^+^IL-7Rα^+^ naïve-like CD8^+^ ([Fig. 1c](#F1){ref-type="fig"}) and CD4^+^ ([Supplementary Fig. 1a](#SD1){ref-type="supplementary-material"}) T cells. In 29 healthy donors, these cells, referred to hereafter as T~SCM~ cells, represented about 2--3% of all circulating CD8^+^ and CD4^+^ T lymphocytes ([Fig. 1d](#F1){ref-type="fig"} and [Supplementary Fig. 1b](#SD1){ref-type="supplementary-material"}). Further phenotypic analysis of T-cell differentiation markers revealed that T~SCM~ also expressed higher levels of BCL-2, LFA-1, CXCR3, CXCR4, and lower levels of CD38 and CD31 compared to T~N~ cells ([Fig. 1e](#F1){ref-type="fig"} and [Supplementary Fig. 1c](#SD1){ref-type="supplementary-material"}). Notably, T~SCM~ cells expressed all of the core phenotypic markers (IL-2Rβ, BCL-2 and CXCR3) of their mouse counterparts^[@R8],[@R9]^, except SCA-1 which does not have a human ortholog. These T cells were phenotypically different from those described by Turtle *et al.*^[@R11]^ and were not MAIT^[@R12]^ ([Supplementary Fig. 2](#SD1){ref-type="supplementary-material"}). Similar to conventional memory, T~SCM~ cells were detected at low frequencies (\<1%) in cord blood ([Supplementary Fig. 3](#SD1){ref-type="supplementary-material"}). The phenotype of T~SCM~ cells indicates a tropism for lymphatic tissues, but full anatomical characterization of T~SCM~-cell niches remains to be addressed.

T~SCM~ possess attributes of conventional memory T cells {#S2}
========================================================

Due to the concomitant expression of numerous markers of naiveté as well as key molecules of memory differentiation, it remained unclear whether T~SCM~ cells were functionally naïve or memory T cells. Naive T cells have high levels of TCR rearrangement excision circles (TREC), which are diluted during clonal proliferation^[@R18]^. Like T~CM~ and T~EM~ cells, we found that T~SCM~ cells had low levels of TREC, indicating that they had undergone several rounds of division ([Fig. 2a](#F2){ref-type="fig"}).

Memory T cells can also be distinguished from T~N~ by their ability to rapidly acquire effector functions upon antigen rechallenge^[@R19]^. We found that within 4h after exposure to Staphylococcus Enterotoxin B (SEB), a significant fraction of CD95^+^ naïve-like CD8^+^ T cells produced IFN-γ, IL-2 and TNF-αs while T~N~ cells remained relatively quiescent ([Fig. 2b,c](#F2){ref-type="fig"}). Thus, T~SCM~ cells rapidly acquired effector functions following superantigen stimulation like conventional memory T cells ([Supplementary Fig. 4](#SD1){ref-type="supplementary-material"}). Interestingly, the fraction of responding cells, as well as T-cell polyfunctionality, progressively increased from T~N~ cells →T~SCM~ cells →T~CM~ cells →T~EM~ cells ([Fig. 2c,d](#F2){ref-type="fig"}), consistent with the hypothesis that T~SCM~ cells are the least differentiated subset. Similar findings were observed for CD4^+^ T cells ([Supplementary Fig. 1d and e](#SD1){ref-type="supplementary-material"}). The rapid responsiveness of T~SCM~ cells was also observed after polyclonal stimulation with α-CD3/CD2/CD28 beads ([Supplementary Fig. 5](#SD1){ref-type="supplementary-material"}). Consistent with the intracellular cytokine staining result, sorted T~SCM~ cells, but not T~N~ cells, secreted IFN-γ, IL-2 and TNF-α in response to α-CD3/CD2/CD28 stimulation ([Supplementary Fig. 6](#SD1){ref-type="supplementary-material"}). Thus, T~SCM~ possess the memory capability of rapid acquisition of effector functions following TCR stimulation.

Unlike T~N~, memory T cells undergo robust proliferation in the presence of the homeostatic cytokines IL-15 and IL-7^[@R20]--[@R22]^. We found that, similar to conventional CD8^+^ memory T cells, T~SCM~ cells divided extensively in response to IL-15 ([Fig. 2e](#F2){ref-type="fig"}). While the majority of T~EM~ cells proliferated ([Fig. 2f](#F2){ref-type="fig"}), they underwent fewer divisions, revealing a lower proliferative potential compared to other memory subsets ([Fig. 2g](#F2){ref-type="fig"}). By contrast, T~SCM~ cells underwent numerous cell divisions ([Fig. 2g](#F2){ref-type="fig"}), although a greater fraction of these cells remained undivided ([Fig. 2f](#F2){ref-type="fig"}). This behavior is reminiscent of stem cells, which are quiescent but can give rise to progeny capable of extensive proliferation and differentiation. Similar findings were observed in the CD4^+^ T-cell compartment in response to IL-7 ([Supplementary Fig. 1f--h](#SD1){ref-type="supplementary-material"}). Thus, T~SCM~ have the replicative history and ability to respond rapidly to antigenic and homeostatic stimuli, characteristics of memory T cells.

The frequency of naïve CD8^+^ T-cell precursors for a given epitope has been estimated to be between 6 × 10^−7^ and 5 × 10^−6^, a range below the limit of peptide-MHC class I (pMHCI) tetramer detection^[@R23]^. We reasoned that if we could measure tetramer-binding, naïve-like T cells, they would be enriched in the CD95^+^ T~SCM~-cell compartment. In donors with detectable naïve-like CD8^+^ T cells specific for influenza or cytomegalovirus (CMV) epitopes, the vast majority of tetramer-binding cells expressed high levels of CD95 ([Fig. 2h,i](#F2){ref-type="fig"} and [Supplementary Fig. 7](#SD1){ref-type="supplementary-material"}). By contrast, virtually all MART-1-specific naïve-like T cells in healthy donors did not express CD95, indicating that these cells were truly naïve ([Fig. 2h,i](#F2){ref-type="fig"} and [Supplementary Fig. 7](#SD1){ref-type="supplementary-material"}). Notably, a significant fraction of MART-1-specific CD8^+^ T cells displayed a CD95^+^ phenotype in 7/11 patients with metastatic melanoma ([Fig. 2h,i](#F2){ref-type="fig"} and [Supplementary Fig. 7](#SD1){ref-type="supplementary-material"}). Thus, tetramer-binding T cells found in the "naive-like" T-cell compartment could be derived from either increased thymic output (CD95^−^), as reported for MART-1 in healthy donors^[@R24]^, or from antigenic encounter, expansion and differentiation (CD95^+^). These experiments also revealed that T~SCM~ represented a substantial fraction of the corresponding total antigen-specific CD8^+^ T-cell memory responses, averaging 0.6% for CMV pp65~495--503~, 4.2% for influenza M1~58--66~ and 7.6% for MART-1~26--35~, and that their frequency tended to correlate with that of conventional memory T cells ([Supplementary Fig. 8](#SD1){ref-type="supplementary-material"}).

To determine whether T~SCM~ clonotypes represent a long-lived population or merely recently activated cells transitioning from a naïve to a conventional memory state, we analyzed TCRβ sequences of CMV-specific T-cell subsets from the same donor spanning a time period of 22 months. Like conventional memory T cells, we found dominant persisting clonotypes in T~SCM~ cells, indicating that they represent a stable memory T-cell population ([Fig. 2j](#F2){ref-type="fig"} and [Supplementary Table 1](#SD1){ref-type="supplementary-material"}). These findings demonstrate that T~SCM~ cells are long-lived memory T cells with multiple viral and self--tumor specificities.

T~SCM~ cells represent the least differentiated T-cell memory subset {#S3}
====================================================================

We sought to compare the transcriptome of T~SCM~ cells with naive and conventional memory T-cell subsets and validate key findings with PFC ([Fig. 3](#F3){ref-type="fig"} and [Supplementary Fig. 9](#SD1){ref-type="supplementary-material"}). Nine hundred genes were differentially expressed among the four CD8^+^ T-cell subsets (*P* \< 0.01, FDR \< 5%) ([Supplementary Table 2](#SD1){ref-type="supplementary-material"}). Unsupervised hierarchical clustering revealed that T~SCM~ cells had a distinct gene expression profile more closely related to conventional memory T cells than T~N~ cells, further corroborating that T~SCM~ cells are a unique T-cell memory subset ([Fig. 3a](#F3){ref-type="fig"}). Consistent with the data reported by Willinger *et al.*^[@R25]^, the majority of genes (565/900) progressively increased (effector-associated genes) or decreased (naïve-associated genes) in the exact order: T~N~ cells →T~SCM~ cells →T~CM~ cells →T~EM~ cells ([Supplementary Table 3](#SD1){ref-type="supplementary-material"}). For example, transcripts of key regulators of effector differentiation and senescence, such as *Eomesodermin*^[@R26]^, *T-box 21*^[@R27]^ and *PR Domain Containing 1, with ZNF Domain*^[@R28]^, as well as genes encoding for cytotoxic molecules (e.g. *Granzyme A* and *Perforin*) and markers of T-cell senescence (e.g. *Killer Cell Lectin-like Receptor Subfamily G, Member 1* (*KLRG1*)^[@R27]^), were increasingly expressed from T~N~ cells to T~EM~ cells ([Fig. 3b](#F3){ref-type="fig"}). Conversely, the expression of transcription factors that inhibit T-cell activation and differentiation such as *Lymphoid Enhancer-binding Factor 1*^[@R9]^ and *Forkhead Box P1*^[@R29]^ and *LAG1 Homolog, Ceramide Synthase 6,* which promotes cellular quiescence by regulating intracellular ceramide levels^[@R30]^, progressively decreased from T~N~ cells to T~EM~ cells ([Fig. 3b](#F3){ref-type="fig"}). These data are consistent with a linear model of T-cell differentiation, in which T~SCM~ are the least differentiated memory T-cell subset.

Multidimensional scaling (MDS) analysis^[@R31]^ confirmed that T~SCM~ cells was the memory T-cell subset most similar to T~N~ ([Fig. 3c](#F3){ref-type="fig"}). Indeed, only 75 genes were differentially expressed between T~N~ and T~SCM~ (*P* \< 0.01 and \> 2-fold change in expression) compared to 157 and 226 for T~CM~ and T~EM~ cells, respectively ([Fig. 3c](#F3){ref-type="fig"}, and [Supplementary Tables 4--6](#SD1){ref-type="supplementary-material"}). T~SCM~ and T~CM~ cells were the most closely related T-cell subsets, with 20 differentially expressed genes ([Fig. 3c,d](#F3){ref-type="fig"} and [Supplementary Tables 4--9](#SD1){ref-type="supplementary-material"}). Among these genes, T~SCM~ cells, like T~N~ cells, expressed low levels of *Heterogeneous Nuclear Ribonucleoprotein L-like*, a key regulator of the alternative splicing of the CD45 pre-mRNA required for efficient CD45RO expression^[@R32]^, confirming the purity of the sorting. When considering this subset of 20 genes, T~SCM~ cells have a pattern of expression similar to T~N~ cells, while T~CM~ cells clustered with T~EM~ cells ([Fig. 3d](#F3){ref-type="fig"}), further underscoring that T~SCM~ cells are less differentiated than T~CM~ cells.

Enhanced self-renewal and multipotency of T~SCM~ cells {#S4}
======================================================

The abilities to self-renew and differentiate into specialized cell types are defining qualities of stem cells. To determine whether T~SCM~ have these stem cell-like properties, we evaluated their capacity to self-renew with homeostatic signals as well as their multipotency after TCR activation. After exposure to IL-15, the vast majority of T~SCM~ cells maintained CD45RA^+^, and retained significantly higher levels of CD62L and CCR7 than T~CM~ cells ([Fig. 4a](#F4){ref-type="fig"} and [Supplementary Fig. 10](#SD1){ref-type="supplementary-material"}). At the end of stimulation about 60% of cells derived from T~SCM~ maintained their phenotypic identity (CCR7^+^CD62L^+^CD45RA^+^CD45RO^−^) while only 30% of T~CM~ cells retained their input phenotype (CCR7^+^CD62L^+^CD45RA^−^CD45RO^+^) ([Fig. 4b](#F4){ref-type="fig"}). T~SCM~ cells also displayed greater self-renewal capacity compared to T~CM~ cells following a secondary exposure to IL-15 ([Supplementary Fig. 11](#SD1){ref-type="supplementary-material"}).

Following α-CD3/CD2/CD28 stimulation, however, T~SCM~ cells gradually upregulated CD45RO over several cell divisions while acutely downregulating CD62L and CCR7 ([Fig. 4c](#F4){ref-type="fig"} and [Supplementary Fig. 10](#SD1){ref-type="supplementary-material"}). These dynamic changes in phenotype resulted in a diverse progeny comprising about 50% of T~CM~ cells and 4% of T~EM~ cells ([Fig. 4d](#F4){ref-type="fig"}). Most importantly, 15% of T~SCM~-derived cells maintained a CCR7^+^CD62L^+^CD45RA^+^CD45RO^−^ phenotype even after this potent stimulus, indicating that T~SCM~ cells have the multipotent capacity to derive all memory T-cell subsets ([Fig. 4d](#F4){ref-type="fig"}). By contrast, T~CM~ cells retained a central memory phenotype or differentiated into T~EM~ cells, but did not generate T~SCM~ ([Fig. 4d](#F4){ref-type="fig"}). Consistent with their advanced differentiation state, T~EM~ cells did not reacquire CD62L or CCR7 and did not dedifferentiate into T~CM~ or T~SCM~ cells after either IL-15 or α-CD3/CD2/CD28 stimulation ([Fig. 4a--d](#F4){ref-type="fig"}). Taken together, these findings indicate that T~SCM~ cells have the stem cell-like properties of self-renewal and multipotency *in vitro* ([Fig. 4e](#F4){ref-type="fig"}).

Increased proliferative capacity, survival and anti-tumor activity of T~SCM~ cells {#S5}
==================================================================================

We previously found that mouse T~SCM~ cells have enhanced proliferative and survival capacities compared with T~CM~ and T~EM~ cells^[@R9]^. To evaluate the replicative responses of T~SCM~ cells we measured the levels of ^3^H-thymidine incorporation after TCR stimulation. As previously reported^[@R33]^, T~CM~ and T~N~ cells displayed increased proliferative responses compared to T~EM~ cells, but they were outpaced by T~SCM~ cells ([Fig. 5a](#F5){ref-type="fig"}). Although assessment of telomerase activity was uninformative ([Supplementary Fig. 12](#SD1){ref-type="supplementary-material"}), we sought to ascertain the long-term replicative and survival capacities of T~SCM~. We adoptively transferred CD8^+^ T-cell subsets into highly immunodeficient NOD.Cg-Prkdc^scid^Il2rg^tm1Wjl^/SzJ (NSG) mice and evaluated T-cell engraftment one month after transfer. We co-transferred CD8-depleted peripheral blood mononuclear cells (PBMC) to provide a source of human cytokines and costimulatory molecules^[@R34]^. Strikingly, we found that T~SCM~ engrafted with 10- to 100-fold more progeny than T~CM~ or T~N~ cells in both lymphoid and non-lymphoid tissues ([Fig. 5b,c](#F5){ref-type="fig"} and [Supplementary Fig. 13](#SD1){ref-type="supplementary-material"}). Notably, T~EM~ cells, which are used in clinical trials for adoptive immunotherapy^[@R35],[@R36]^, had a poor proliferative and survival capability with engraftment comparable to the contaminating CD8^+^ T-cell population from the co-transferred CD8-depleted PBMC. This humanized mouse model, however, is inadequate to test T-cell self-renewal *in vivo* because all CD8^+^ T-cell subsets uniformly differentiated into effector cells ([Supplementary Fig. 14](#SD1){ref-type="supplementary-material"}) likely as a result of encounter homeostatic cytokines and with xenogeneic major histocompatibility antigens. Nonetheless, adoptive transfer in NSG mice prove that T~SCM~ cells have enhanced replicative and survival capabilities compared to naïve and conventional memory subsets.

T-cell proliferative and survival capacities correlate with the anti-tumor efficacy of adoptively transferred T cells^[@R35]--[@R39]^. T cell receptor (TCR) or chimeric antigen receptor (CAR) gene engineering are currently used in the clinic to redirect the specificity of circulating T cells toward the desired target^[@R36],[@R40],[@R41]^. We exploited this approach coupled to the pharmacological activation of Wnt signaling to generate high numbers of mesothelin-specific *ex vivo*-generated T-cell memory subsets ([Supplementary Fig. 15](#SD1){ref-type="supplementary-material"}) to test in a xenograft tumor model that we recently established^[@R34]^. Mesothelin-specific T~SCM~, T~CM~ or T~EM~ cells were co-transferred with mesothelin-specific CD4^+^ T cells into NSG mice bearing luciferase-expressing M108 mesothelioma established for 3 months in the peritoneum. To generate a treatment window, we administered 3×10^6^ CD8^+^ T cells and 10^6^ CD4^+^ T cells, 10-fold fewer cells than previously published^[@R34]^. T~EM~ mediated poor anti-tumor responses as indicated by the increased intensity of the bioluminescent signal in the abdomen ([Fig 5d](#F5){ref-type="fig"}) and the ascites-dependent weight gain ([Fig. 5e](#F5){ref-type="fig"}). Furthermore, transfer of T~EM~ did not significantly extend the survival of the animals compared to CD4^+^ T cells alone ([Fig. 5f](#F5){ref-type="fig"}). T~CM~ cells were more effective than T~EM~ cells and improved survival, although all mice died from tumor progression within 40 days after treatment ([Fig. 5d--f](#F5){ref-type="fig"}). In stark contrast, T~SCM~ cells triggered tumor regression and cure in mice that otherwise died within two to three weeks ([Fig. 5d--f](#F5){ref-type="fig"}). Late mortality of mice receiving T~SCM~ cells was ascribed to the development of xenogeneic graft-versus-host disease as manifested by loss of body weight ([Fig. 5d,e](#F5){ref-type="fig"}). Thus, adoptively transferred T~SCM~ cells have enhanced anti-tumor activity and are more therapeutically effective than conventional T~CM~ and T~EM~ cells.

Discussion {#S6}
==========

We identified a long-lived human memory T-cell subset found within the naïve-like T-cell compartment. Once thought to be homogenous, the so-called "naïve T cell subset" is emerging as a complex amalgamation of cell types, including recent thymic emigrants^[@R42],[@R43]^, "super-naïve" CD44^very\ low^ T cells^[@R44]^, and CXCR3^+^ or CCR4^+^ early memory cells^[@R45]^. Evidence presented here indicates that T~SCM~ are a clonally expanded primordial memory subset arising after antigenic stimulation with increased proliferative and reconstitutive capacities. T~SCM~ cells have enhanced self-renewal, and the multipotency to generate all memory and effector T-cell subsets *in vitro*. These qualities are all consistent with stem cell-like behavior, but formal proof of "stemness" *in vivo* will have to await clinical trials involving the adoptive transfer of T~SCM~ and assessment of long-term self-renewal and repopulating potential. Nevertheless, the qualities of human T~SCM~ cells that we have measured are consistent with those of mouse T~SCM~ cells that displayed enhanced self-renewal and multipotency in serial transplantation experiments^[@R8],[@R9]^.

Given the young age at which the thymus involutes in humans relative to life expectancy, the presence of such a long-lived less differentiated memory T-cell population might ensure protection against pathogens throughout life. Indeed, the vast majority of naïve-like T cells in centenarians express high levels of CD95^[@R46]^, a phenotype consistent with the T~SCM~ described here.

Expression of CD95 by long-lived memory T cells might seem perplexing because of its well established pro-apoptotic function. However, the outcome of FAS ligand-CD95 interaction might be dependent on the differentiation state of the cellular substrate, as observed in other organ systems^[@R47]^. CD95 triggers apoptosis in terminally differentiated neurons through the formation of a death-inducing complex, but promotes cell proliferation in neural progenitors and cancer stem cells by inducing TCF/β-catenin signaling^[@R47]^. Considering the emerging role of TCF/β-catenin signaling in the formation and maintenance of memory T cells^[@R9],[@R14],[@R48],[@R49]^, CD95 might not only demarcate memory T cells but also be functionally important for their self-renewal and persistence.

The finding that T~SCM~ cells have enhanced proliferative capacity and can sustain the generation of all memory and effector T-cell subsets has considerable implications for the design of T cell-based vaccines to target intracellular pathogens and cancer. Heterologous prime-boost approaches have been used to increase the frequency of memory T cells but they have the undesired effect of driving T cells toward a state of terminal differentiation^[@R3],[@R50],[@R51]^, which compromises their ability to clear systemic infections^[@R52],[@R53]^ and eradicate tumors^[@R37]^. The use of small molecules targeting the mTOR ^[@R54],[@R55]^ and Wnt^[@R14],[@R56]^ signaling pathways might improve vaccines by modulating T-cell differentiation and enriching for T~SCM~ and T~CM~ cells. Finally, by coupling TCR or CAR gene-engineering technology^[@R36],[@R40],[@R41]^ with the pharmacologic modulation of T-cell differentiation^[@R56]^, we have demonstrated a feasible and translatable strategy for the *in vitro* generation of highly effective T~SCM~-like cells to use in adoptive T-cell therapy trials for the treatment of cancer and infectious diseases.

METHODS {#S7}
=======

Antibodies, flow cytometry and cell sorting {#S8}
-------------------------------------------

We obtained all human samples from healthy donors or patients enrolled in clinical trials approved by the NCI Institutional Review Board. We conjugated unlabeled antibodies (BD Biosciences) in our laboratory reported at <http://www.drmr.com/abcon>. We purchased fluorescently-conjugated antibodies from BD Biosciences, eBioscience, Biolegend, Invitrogen and Beckman Coulter. Except for MART-1^[@R26]--[@R35]^ (27L) (Beckman Coulter), we produced recombinant pMHCI tetramers as described previously^[@R57]^. We performed surface and intracellular staining as described previously^[@R22]^. We measured cytokine release using the cytometric bead array/human Th1/Th2/Th17 cytokine kit (BD Biosciences). We performed flow cytometry acquisition on a modified LSR II, equipped to detect 18 fluorescencet parameters. We compensated and analyzed data with FlowJo software (Treestar Inc.). We sorted T cell subsets using a modified FACSAria (BD Biosciences).

*In vitro* generation of T~SCM~-like cells {#S9}
------------------------------------------

We stimulated CD45RO^−^CD62L^+^ cells with α-CD3/CD28 beads (Invitrogen) at 1:1 bead-to-cell ratio and 300 IU ml^−1^ IL-2 (Chiron) in the presence of 5 µM TWS119 (Cayman Chemical) for two weeks.

Animal experiments {#S10}
------------------

We conducted all animal experiments with the approval of the NCI or University of Pennsylvania Institutional Animal Use and Care Committees. We used NOD.Cg-Prkdc^scid^Il2rg^tm1Wjl^/SzJ mice (NSG) (The Jackson Laboratory) as recipients for adoptive transfer experiments.

Generation of mesothelin-specific T cells {#S11}
-----------------------------------------

We stimulated T cells with α-CD3/CD28 beads at 1:3 cell to bead ratio and 20 IU ml^−1^IL-2. We transduced T cells with lentiviral vectors encoding for the anti-mesothelin chimeric receptor SS1:BB:TCR-ζ^[@R34]^ 24h after activation and added 5µM TWS119 12h after transduction. Cells were fed every other day with TWS119 and IL-2 for two weeks. We purified CD8^+^ T memory subsets using MACS positive selection Multisort kits (Miltenyi Biotec). Approximately 2 × 10^6^ CD8^+^ T cell subsets were mixed with 10^6^ unsorted CD4^+^ T cells and injected i.v. into tumor-bearing NSG mice.

Mouse xenograft studies {#S12}
-----------------------

We engineered the M108-km1 human mesothelioma cell line^[@R34]^ with a lentiviral vector to express firefly luciferase, yielding the M108-Luc cell line. Animals were injected i.p. with 8 × 10^6^ M108-Luc cells. We measured tumor burden by bioluminescent imaging and body weight.

Bioluminescence imaging {#S13}
-----------------------

We injected mice i.p. with 150 mg kg^−1^ body weight D-luciferin (Caliper Life Sciences) and imaged 10--12 minutes later using a Xenogen Spectrum system and Living Image v3.2 software (Caliper Life Sciences).

Determination of T cell replicative history {#S14}
-------------------------------------------

We determined the replicative history of sorted subsets by quantifying T cell receptor rearrangement excision circles (TREC) using real time qPCR as described previously^[@R18]^.

Clonotypic analysis of antigen-specific CD8^+^ T cell populations {#S15}
-----------------------------------------------------------------

We amplified *TRB* gene products of sorted NV9-specific CD8^+^ T cell subsets using a template-switch anchored RT-PCR and performed subcloning, sequencing and analysis as described previously^[@R57]^. TCR nomenclature was translated directly from the IMGT database (The ImmunoGeneTics information system® <http://imgt.cines.fr>) using web-based alignment of molecular TRB transcripts.

Whole genome gene expression analysis {#S16}
-------------------------------------

Total RNA from sorted CD8^+^ T cell subsets was isolated using an RNEasy Micro kit (Qiagen), processed using a WT expression kit (Ambion), fragmented and labeled using a WT Terminal Labeling Kit (Affymetrix), hybridized to WT Human Gene 1.0 ST arrays (Affymetrix) and stained on a Genechip Fluidics Station 450 (Affymetrix). We scanned arrays on a GeneChip Scanner 3000 7G (Affymetrix). We imported the raw data from. CEL files into the Partek Genomincs Suite using the RMA method. We identified differentially expressed genes (DEGs) by One-Way Repeated Measures ANOVA (*P* \< 0.01) corrected by Benjamini-Hochberg\'s False Discovery Rate method (*P* \< 0.05). For pair-wise comparisons, we further filtered genes for between-group alpha levels of *P* \< 0.01 and a fold change criterion of \> 2.0. We deposited array data at the Gene Expression Omnibus (GEO) public depository under the accession number GSE23321.

Analysis of T cell proliferation {#S17}
--------------------------------

We determined cell proliferation by ^3^H-thymidine incorporation and by 5-(and 6)-carboxyfluorescein diacetate succinimidyl ester (CFSE) dilution. In the former case, we stimulated cells for 24 hours with α-CD3/CD2/CD28-coated beads (Miltenyi Biotec), then pulsed with ^3^H-thymidine (1 µCi; Perkin Elmer) for an additional 16 hours. We harvested supernatants and determined counts per minute with a β-scintillation counter (Perkin Elmer). In the latter, we labeled cells with 2 µM CFSE for 7 minutes at 37°C and stimulated them with αCD3/CD2/CD28-coated beads (Miltenyi Biotec) for 6 days or with rhIL-7 or rhIL-15 (both 25 ng ml^−1^; Peprotech) for 14d and 10d, respectively. We determined proliferation index, and percentage of divided cells with FlowJo.

Statistical analysis {#S18}
--------------------

We performed statistical analyses using Prism (GraphPad Software) and Spice software. For most of the comparison we used a non-parametric Wilcoxon rank test to compare two groups. We employed One ANOVA to compare three or more groups and χ^2^ permutation test for pie-chart comparison^[@R58]^. We used non-parametric Spearman's rank correlation test to measure statistical correlation between two groups and Kaplan-Meier method to analyze survival.
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![Identification of T~SCM~ cells in human blood\
**a**, Flow cytometry analysis of sorted human CD45RO^−^CD62L^+^ naïve CD8^+^ T cells prior to and 14 days after stimulation with α-CD3/CD2/CD28-coated beads and IL-2 in the presence or absence of 5µM TWS119. Numbers indicate the percentage of cells in the CD45RO^−^CD62L^+^ gate. **b**, Flow cytometry analysis of TWS119-generated CD45RO^−^CD62L^+^ naïve-like CD8^+^ T cells overlaid with CD45RO^−^CD62L^+^ naïve and memory (non-CD45RO^−^ CD62L^+^) cells from a healthy donor (HD). **c**, Flow cytometry analysis of PBMC from a healthy donor. Dot plots show the gating strategy to identify CD95^+^, IL2Rβ^+^ T~SCM~ cells. **d**, Percentages of circulating CD8^+^ T-cell subsets in 29 healthy donors. **e**, Flow cytometry analysis of PBMC from a representative healthy donor. Overlaid histogram plots show expression levels of a given molecule in different CD8^+^ T-cell subsets. CD8^+^ T-cell subsets were defined as follows: T~N~ cells, CD3^+^CD8^+^CD45RO^−^CCR7^+^CD45RA^+^CD62L^+^CD27^+^CD28^+^IL7Rα^+^CD95^−^; T~SCM~ cells, CD3^+^CD8^+^CD45RO^−^CCR7^+^CD45RA^+^CD62L^+^CD27^+^CD28^+^IL7Rα^+^CD95^+^; T~CM~ cells, CD3^+^CD8^+^CD45RO^+^CD45RA^−^ CCR7^+^CD62L^+^; T~EM~ cells, CD3^+^CD8^+^CD45RO^+^CD45RA^−^CCR7^−^CD62L^−^.](nihms312734f1){#F1}

![T~SCM~ cells possess attributes of conventional memory T cells\
**a**, TCR excision circle (TREC) copy number in sorted CD8^+^ T-cell subsets relative to T~N~ cells. Data are represented as mean ± s.e.m. of 4 donors. **b**, Intracellular cytokine staining of PBMC from a representative healthy donor after stimulation with SEB. Graphs show naïve-like (NL) gated T cells. NL, CD45RO^−^CCR7^+^CD45RA^+^CD27^+^CD28^+^. Numbers represent the percentage of CD95^+^ (T~SCM~) and CD95^−^ (T~N~) cells producing a single cytokine. **c**, Percentages of CD8^+^ T-cell subsets producing IFN-γ, IL-2 and TNF-α in 6 healthy donors (obtained as described in panel **b**). **d**, Pie charts depicting the quality of the cytokine response in CD8^+^ T-cell subsets in 6 healthy donors as determined by the Boolean combination of gates identifying IFN-β^+^, IL-2^+^ and TNF-α^+^ cells. **e**, CFSE dilution in sorted CD8^+^ T-cell subsets after stimulation with 25 ng ml^−1^ of IL-15 for 10 days. Data are shown after gating on CD8^+^ cells. PD: percentage divided; PI: proliferation index. **f**, Percentage divided cells and **g**, Proliferation index of different CD8^+^ T-cell subsets after stimulation as in panel **e**. Data are represented as means ± s.e.m of 9 donors. **h**, Flow cytometry analysis of PBMC from HLA-A2^+^ donors. Graphs show tetramer-binding cells vs. CD95 expression in the NL (CD45RO^−^CCR7^+^CD45RA^+^CD27^+^IL7Rα^+^) gate. **i**, Percentage of tetramer-binding cells expressing CD95 in the NL gate determined as in panel **h**. Data represent the donors tested for tetramer specificity. HD: healthy donor; MP: melanoma patient. **j**, Frequency of two immunodominant CMV-specific TCRβ clonotypes relative to all CMV-specific TCRβ clonotypes in pp65 -specific T-cell subsets isolated over a period of 22 months from a representative donor. The figure legend shows the CDR3β amino acid sequences. Changes in the frequencies of immunodominat clonotypes are depicted as the thickness of the bars, with the magnitude scale shown on the right. \* = *P* \< 0.05; \*\* = *P* \< 0.01; \*\*\* = *P* \< 0.001; ns= not significant (t test, **c,f,g,I** and χ^2^ permutation test, **d**).](nihms312734f2){#F2}

![T~SCM~ cells represent a distinct, less differentiated T-cell memory subset\
**a**, Heat map of differentially expressed genes (*P* \< 0.01 One-Way Repeated Measures ANOVA, FDR \< 5% Benjamini-Hochberg\'s method) among CD8^+^ T-cell subsets. Red and blue colors indicate increased and decreased expression respectively. **b**, Robust Multichip Analysis (RMA)-normalized intensity of selected display of genes progressively downregulated (naïve associated genes) or upregulated (effector associated genes) from T~N~ cells →T~SCM~ cells →T~CM~ cells →T~EM~ cells. Data are represented as means ± s.e.m of 3 donors. **c**) Multidimensional scaling (MDS) analysis of differentially expressed genes (*P* \< 0.01, FDR \< 5%). Numbers represent the differentially regulated genes among each CD8^+^ T-cell subset (*P* \< 0.01 (t test) and \> 2 fold change in expression level). *d*, Heat map of differentially-expressed genes among T~SCM~ and T~CM~ cells (*P* \< 0.01 (t test) and \> 2 fold change in expression level). Red and blue colors indicate increased and decreased expression, respectively. Full gene names are listed in the [Supplementary Information](#SD1){ref-type="supplementary-material"}.](nihms312734f3){#F3}

![Enhanced self-renewal and multipotency of T~SCM~ cells\
**a**, Percentage of CD8^+^ T cells expressing CCR7 and CD62L (right panel) and CD45RA (left panel) relative to cell division after exposure to 25ng ml^−1^ of IL-15 for 10 days. Slopes (S) were compared using a Wilcoxon rank test, \*= *P* = 0.0391. $s = \frac{\sum\limits_{i}^{n}(\textit{gi} - \overline{g})(\textit{pi} - \overline{p})}{\sum\limits_{i}^{n}{(\textit{gi} - \overline{g})}^{2}}$ where *g* = generation number and *p* = percentage of CD62L^+^CCR7^+^ cells (*n* = 8). **b**, Percentage of CFSE-diluted CD8^+^ T cells that retained the parental phenotype following stimulation with 25ng ml^−1^ of IL-15 for 10 days. **c**, Percentage of CD8^+^ T cells expressing CCR7 and CD62L (right panel) and CD45RA (left panel) relative to cell division after stimulation with α-CD3/CD2/CD28-coated beads for 6 days. **d**, Percentage of CFSE-diluted CD8^+^ T cells with a given phenotype following stimulation with α-CD3/CD2/CD28-coated beads for 6 days. **e**, Stemness index of CD8^+^ memory T-cell subsets. Stemness index was calculated by multiplying self-renewal (SI) and multipotency (MI) indexes. SI was calculated as follows: SI= 2^PI^P~RP~, PI=Proliferation index, P~RP~= Percentage of cells retaining the input phenotype and MI was calculated as the net entropy of the progeny T-cell subsets $\text{MI} = \sum\limits_{i}^{n} - pi\,\text{ln}\, pi$ where *p* = percentage of a given T-cell subset generated following α-CD3/CD2/CD28 stimulation. Data are represented as mean ± s.e.m of 4 donors; \* = *P* \< 0.05 (t test) (*n* = 4).](nihms312734f4){#F4}

![Increased proliferative capacity, survival and antitumor activity of T~SCM~ cells\
**a**, ^3^H-thymidine incorporation by sorted CD8^+^ T-cell subsets after stimulation with α-CD3/CD2/CD28-coated beads. Data are represented as means ± s.e.m of 10 donors. Results are normalized to the number of seeded cells, as different cell numbers were obtained from different sorts. \* = *P* \< 0.05; \*\* = *P* \< 0.01; \*\*\* = *P* \< 0.001 (t test) **b**, Flow cytometry analysis of human T cells in the spleen, lymph nodes (LN) and liver of a representative NSG mouse at 4 weeks following adoptive transfer of CD4^+^ T cells (5 × 10^6^) with or without sorted CD8^+^ T-cell subsets (10^6^). Graphs show T cells after gating on human CD45^+^ cells. Numbers indicate the percentage of cells in the CD4^+^CD8^−^ or CD4^−^CD8^+^ gates. **c**, Total human CD8^+^ T-cell recovery in the spleens, LN and livers from 6 NSG mice 4 weeks following adoptive transfer of CD4^+^ T cells with or without sorted CD8^+^ T-cell subsets. A total of 6 mice per T-cell subset from two independent experiments (3 replicate mice per T-cell subset per experiment) are shown. Horizontal bars indicate median values. \* = *P* \< 0.05; \*\* = *P* \< 0.01 (t test) **d--f**, *In vivo* bioluminescent imaging (**d**), percentage change of body weight (**e**), and survival of NSG mice (**f**) bearing M108-luciferase mesothelioma after adoptive transfer of CD4^+^ T cells (10^6^) with or without sorted CD8^+^ T-cell subsets (3 × 10^6^) expressing a mesothelin-specific chimeric antigen receptor. \*\*\* = *P* \< 0.001 One-Way Repeated Measures ANOVA (**e**) and Log-rank (Mantel-Cox) Test (**f**).](nihms312734f5){#F5}
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